Research ArticleEndocrine and Diabetes
SCO-267, a GPR40 full agonist, improves glycemic and body weight control in rat models of diabetes and obesity
Hikaru Ueno, Ryo Ito, Shin-Ichi Abe, Mitsugi Ookawara, Hirohisa Miyashita, Hitomi Ogino, Yasufumi Miyamoto, Tomoki Yoshihara, Akihiro Kobayashi, Yoshiyuki Tsujihata, Koji Takeuchi, Masanori Watanabe, Yukio Yamada, Tsuyoshi Maekawa, Nobuhiro Nishigaki and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics June 10, 2019, jpet.118.255885; DOI: https://doi.org/10.1124/jpet.118.255885
Hikaru Ueno
1 Takeda Pharmaceutical Company Limited;
Ryo Ito
1 Takeda Pharmaceutical Company Limited;
Shin-Ichi Abe
2 SCOHIA PHARMA Inc.;
Mitsugi Ookawara
2 SCOHIA PHARMA Inc.;
Hirohisa Miyashita
1 Takeda Pharmaceutical Company Limited;
Hitomi Ogino
1 Takeda Pharmaceutical Company Limited;
Yasufumi Miyamoto
1 Takeda Pharmaceutical Company Limited;
Tomoki Yoshihara
1 Takeda Pharmaceutical Company Limited;
Akihiro Kobayashi
2 SCOHIA PHARMA Inc.;
Yoshiyuki Tsujihata
1 Takeda Pharmaceutical Company Limited;
Koji Takeuchi
1 Takeda Pharmaceutical Company Limited;
Masanori Watanabe
2 SCOHIA PHARMA Inc.;
Yukio Yamada
2 SCOHIA PHARMA Inc.;
Tsuyoshi Maekawa
2 SCOHIA PHARMA Inc.;
Nobuhiro Nishigaki
1 Takeda Pharmaceutical Company Limited;
Yusuke Moritoh
3 SCOHIA PHARMA, Inc.
Data Supplement
- Supplemental Figures -
Figures S1-S6.